Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Chronic Hepatitis C (HCV) affects several thousand people in Brazil and Colombia. New therapies allow cure in a short period of time with minimal side effects, in contrast to older options. Brazil updated the HCV clinical guidelines in 2015, and Colombia has recently started prioritizing this disease. Both countries are eager to adopt new technologies, but are also undergoing economic hardships. Likewise, Colombia’s plan of benefits will soon experience significant changes, and ongoing discussions may freeze the healthcare budget in Brazil. Hence, only drugs meeting payers’ and physicians’ clinical and economic expectations will succeed in this highly profitable, yet competitive, market. This Access and Reimbursement analysis provides key insights for navigating the chronic HCV therapy market in Brazil and Colombia, and for adapting a branded therapy’s value message to payers and physician needs and expectations in each country.
Decision Resources Group’s Access and Reimbursement module for the hepatitis C virus in Brazil and Colombia explores the prescribing patterns for current chronic HCV therapies, the potential impact of the anticipated arrival of novel therapies, and key national and regional market access factors that will shape the use of chronic HCV therapies over the next two to three years. This report draws on insights from 103 surveyed physicians and from interviews with six payers in Brazil and Colombia, all of whom have influence at the regional or national level.
Markets covered: Brazil and Colombia
Questions Answered in This Report:
Already a Client? Log in to access this report.
Nuno T. Antunes, , is senior business insights analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in antibacterial agents. Previously, he was a Latin America Market Access senior analyst in the Global Market Access Insights Team, where he developed expertise in market access, pricing and reimbursement, health technology assessment, and health policy. Nuno holds a in animal health from the Universidad de las Palmas de Gran Canaria, Spain, and a degree from the Universidade de Trás-os-Montes e Alto Douro, Portugal. Prior to joining DRG, he conducted research in antimicrobial resistance and antimicrobial development, and worked in the medical devices industry as a scientist.